Steven Julious

Professor of Medical Statistics at The University of Sheffield and NIHR Senior Investigator. Statistician, walker and Garibaldi Red. The opinions are personal

[Steven Julious @StevenJulious]

Have just received the authors copy the 2nd edition of my book.

Sample Sizes for Clinical Trials

It is due out 21 June

#statstwitter #epitwitter #ClinicalTrials #clinicalresearch @ScHARRSheffield @ScHARR_DTS @CTRU_Sheffield

[Steven Julious @StevenJulious]

If anyone can help with this survey or school age children it would be appreciated

Please share and/or post to any persons or groups that may be interested....

[Steven Julious @StevenJulious]

Had a paper published with @Flight_LG and @Alan_Brennan entitled

Value-adaptive clinical trial designs for efficient delivery of publicly funded trials - a discussion of methods, case studies, opportunities and challenges

https://t.co/ClAICWzYBC

[Steven Julious @StevenJulious]

The protocol for MissionEB - a randomised, double-blinded, placebo-controlled, two-centre, crossover trial - a study to assess mesenchymal intravenous stromal cell infusions in children with recessive dystrophic epidermolysis bullosa has been published

https://t.co/sXQ162pPLP

[Steven Julious @StevenJulious]

A great talk by @JamesSalsbury at #sct2025 entitled

Assurance methods for designing a survival trial with delayed treatment effects

[Steven Julious @StevenJulious]

Attending an excellent talk by @NikkiTotton entitled at #SCT2025 entitled

Using benefit risk methods to adjust the non-inferiority margin based on treatment benefits

[Steven Julious @StevenJulious]

We recommend that the conditional frailty model be used for these data in trials, including cluster randomised trials, to help
to explain changes in event risk over time and assist clinical interpretation

[Steven Julious @StevenJulious]

Had a paper published with Kelly Grant on the analysis of recurrent events in clinical trials

https://t.co/jnZVTRUTwM

[Marion Campbell @MarionKCampbell]

In clinical trials it is not only potential benefits that should be measured - it is crucially important that any potential #harms are also investigated 1/7
#MethodologyMonday #118

[StatsCI @stats_ci]

New Publication 🔊: Trials special series - the collection, analysis and reporting of adverse events in randomised controlled trials by @RachPips & @VR_Cornelius https://t.co/gfD8cDV9yK

[Steven Julious @StevenJulious]

Today's date

5-2-25

Is a palindrome

[Steven Julious @StevenJulious]

My PhD student is undertaking a DELPHI on reporting of sample sizes with studies with adaptive designs in protocols and grants. Please fill in if you can

[qiang zhang @qiangzh83769692]

This sub-study is part of a PhD project at the University of Sheffield, supervised by Prof. Steven Julious (@StevenJulious ) and Dr. Munya Dimairo (@mdimairo )
Please feel free to reach out to our team.
Email: [email protected]
#AdaptiveTrials #TrialDesign #SampleSize

[Steven Julious @StevenJulious]

Just had a paper published led by @HollyTibble with researchers from @AUKCAR on using routine data in research

[Holly Tibble @HollyTibble]

New Paper! Routinely recorded primary care data can be used to evaluate interventions provided within routine care, anecdotally researchers in the @AUKCAR have encountered multiple barriers to access and use.
https://t.co/wBTNXlZxBK

[Steven Julious @StevenJulious]

My paper with Amy Whitehead Mike Campbell & Cindy Cooper

Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable

Has been cited 1000 times

https://t.co/VyBZQP6zAC

[Steven Julious @StevenJulious]

@DrLauraAGray Congratulations Laura

[Steven Julious @StevenJulious]

Nearly half of studies did not justify their non-inferiority limit

[Steven Julious @StevenJulious]

Just had a paper published entitled "A review of UK publicly funded non-inferiority trials: is the design more inferior than it should be?"

Led by Nikki Totton with Stephen Walters and Elizabeth Coates

https://t.co/g2ejmilMXB

[Steven Julious @StevenJulious]

The paper found the use of term "non-inferioroity" increased with the publication of the CONSORT Non-inferiority Guidelines

[Steven Julious @StevenJulious]

The timing of the first inteim analysis between industry and publicly funded trials is quite marked. For industry studies the first interim is after 50% of the information fration. By comparison for publicly funded trials the timing is bi-modal

[Steven Julious @StevenJulious]

Justed had paper published with @qiangzh83769692 , @mdimairo , Jen Lewis and Zihang Yu entitled

"Reporting and communication of sample size calculations in adaptive clinical trials: a review of trial protocols and grant applications"

https://t.co/oXpiJ9PSv5

[Steven Julious @StevenJulious]

For industry studies 68% have just one interim analysis compared to 51% for publicly funded